Tenax Therapeutics (TENX)

$18.27 +3.22 (21.40%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	91.78M
Revenue (ttm)	0.00
Net Income (ttm)	-17.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,283,700
Avg Vol	173,342
Day's Range	N/A - N/A
Shares Out	6.24M
Stochastic %K	89%
Beta	1.34
Analysts	Strong Sell
Price Target	$25.25

Company Profile

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was former...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 855 2100

Website: www.tenaxthera.com

Address:

101 Glen Lennox Drive, Suite 300, Chapel Hill, United States

Godwins26 Jan. 14 at 11:34 PM

$TENX look to $IVP up 256% for a bullish after hours run🚀

0 · Reply

Narutoosaka Jan. 14 at 10:48 PM

$TENX New Insider Option Grant • A Form 4 filing today shows that director Robyn Hunter was granted 30,000 stock options exercisable at $13.30/share. • These options vest starting January 9, 2027 and expire January 9, 2036. • This is not a cash buy; it’s a compensation-related option grant rather than an open-market purchase.

0 · Reply